Stockscreener 앱 받기
0.3915
5.55%
0.0206
시장 영업 전:
.39
-0.0015
-0.38%
Tscan Therapeutics Inc 주식(TCRX)의 최신 뉴스
TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme StudySlideshow (NASDAQ:TCRX) 2026-09-04 - Seeking Alpha
Tscan Therapeutics Inc (NASDAQ: TCRX) Stock Price, News & Analysis - kalkine.com.au
Layoff Tracker: TScan axes 75% of workforce, prioritizes solid tumor program - BioSpace
TScan Therapeutics Cuts 75% of Staff, Pivots to In Vivo TCR-T for Solid Tumors - BioPharm International
TCRX Downgraded by Wedbush -- Price Target Lowered to $1.00 - GuruFocus
Tscan prioritizes in vivo solid tumor program - BioWorld News
TScan Therapeutics IncExpects to Incur Abo - Moomoo
TScan Therapeutics sheds majority of staff, pauses Phase 3 trial amid funding shortfall - The Business Journals
Tscan Therapeutics stock rating cut to neutral by Wedbush on strategy shift - Investing.com Nigeria
Crude Oil Moves Higher; US Factory Orders Rise In July - Benzinga
TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction - Benzinga
Why is TScan Therapeutics stock collapsing today? By Investing.com - Investing.com Canada
TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program - Yahoo Finance
TScan Therapeutics Restructures to Focus on Solid Tumors - TipRanks
TScan Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
All 13 tracked patients show full donor-cell replacement. TScan is cutting 75% of its workforce. - Stock Titan
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation - Barchart.com
TScan Therapeutics (TCRX) Holds at $0.75 as Biotech Stock Defends Key SupportWave Extension - vinanet.vn
Why Is Amgen (AMGN) Ending Its Crohn's Disease Research Partnership? - Yahoo Finance
Is Amgen (AMGN) Refocusing Its R&D Portfolio With The Exit From TScan’s Crohn’s Deal? - simplywall.st
Amgen abandoning $500M+ Crohn’s collab won’t derail TScan’s pipeline strategy - Fierce Biotech
Amgen cans its TScan partnership; Amylyx reveals $350M offering - Endpoints News
TScan Therapeutics Faces Loss of Key Amgen Partnership - TipRanks
TScan TherapeuticsAmgen To Terminate Research Collaboration And License Agreement With TScan TherapeuticsSEC Filing - TradingView
TScan (NASDAQ: TCRX) loses Amgen Crohn’s collaboration - Stock Titan
Analysts Conflicted on These Healthcare Names: Alpha Cognition Inc (ACOG) and TScan Therapeutics (TCRX) - theglobeandmail.com
TScan Therapeutics (TCRX) Edges Higher, Holding Support at $0.74Up Down Volume - vinanet.vn
Lynx1 Capital discloses 13.1% position in TScan Therapeutics (TCRX) common stock - Stock Titan
Biotechnology Value Fund group (TCRX) reports 9.99% TScan ownership with large warrants - Stock Titan
Equities Analysts Set Expectations for TCRX FY2026 Earnings - MarketBeat
H.C. Wainwright reiterates Tscan Therapeutics stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Tscan Therapeutics stock rating at buy - Investing.com
Tscan Therapeutics earnings beat by $0.03, revenue fell short of estimates - Investing.com Nigeria
TScan Therapeutics, Inc. (TCRX) stock price, news, quote and history - uk.finance.yahoo.com
TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of "Hold" by Brokerages - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) Releases Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
TScan Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
TScan Therapeutics, Inc. (TCRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wedbush reiterates Outperform on TScan Therapeutics - scanx.trade
TScan Therapeutics Q2 Results: Sales Fall 66% YoY, EPS Misses - scanx.trade
TScan Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Form 8K Tscan Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
TScan Therapeutics, Inc. 2Q 2026: Revenue $1.05M, Net loss $30.36M, EPS $(0.23) — 10-Q Summary - TradingView
TScan Therapeutics (TCRX) narrows loss but warns on going-concern outlook and debt - Stock Titan
TScan Therapeutics reports Q2 2026: $1.1M revenue, $30.4M net loss, cash $100.2M - TradingView
TScan Therapeutics Reports $30.4 Million Q2 Net Loss - Quiver Quantitative
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
TScan Therapeutics (TCRX) narrows Q2 2026 loss and doses first patient in Phase 3 ALLOHA-2 trial - Stock Titan
TScan Therapeutics Q2 net loss narrows on lower R&D costs - TradingView
TScan Therapeutics Reports First Patient Dosed in Phase 3 ALLOHA-2 Study and Second-Quarter 2026 Results - Quiver Quantitative
TScan Therapeutics (TCRX) Edges Higher as Price Holds Above Key $0.73 SupportRegression Channel - dars.gov.et
TScan Therapeutics Inc (TCRX) Stock News Today - TradingKey
TScan Therapeutics Inc (TCRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TScan Therapeutics Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
TScan Therapeutics (TCRX) Climbs 4.5% to $0.77, Testing Key Resistance ZoneStatistical Arbitrage - dars.gov.et
Short Interest in TScan Therapeutics, Inc. (NASDAQ:TCRX) Expands By 95.5% - MarketBeat
TScan doses first patient in phase 3 AML, MDS trial By Investing.com - Investing.com Nigeria
0.86%
0.31%
자본화:
|
볼륨(24시간):